BioNxt Solutions Announces Convertible Debenture Unit Private Placement

About this update from Bionxt Solutions Inc

[{"type":"text","content":"NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES","length":98,"tagName":"p"},{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), is pleased to announce its intention to complete a non‐brokered private placement (the "Offering") of convertible debenture units (the "Debenture Units") at a price of $0.60 per Debenture Unit, for gross proceeds of up to $1,200,000.","length":410,"tagName":"p"},{"type":"text","content":"Each Debenture Unit consists of: (i) $0.60 principal amount of 8.0% unsecured convertible debentures (the "Debentures") and (ii) one common share purchase warrant (each a "Warrant"). Each Warrant entitles the holder to acquire one common share in the capital of the Company (a "Common Share") at a price of $0.75 per Common Share for a period of two years following the date of issuance. The Debentures bear interest from their issue date at 8.0% per annum on an accrual basis, calculated and payable on an annual basis, up to and including the date which is two years following the date of issuance (the "Maturity Date"). The principal amount of the Debentures is convertible, at the option of the holder, into Common Share at any time prior to the Maturity Date, at a conversion price of $0.60 per Common Share (the "Conversion Price"). At the election of the Company, the interest payable on the principal amount of the Debentures may be settled by a cash payment or through the issuance of Common Shares at the Conversion Price.","length":1082,"tagName":"p"},{"type":"text","content":"The Company intends to use the net proceeds from the Offering for product development and commercialization, intellectual property filings, and general working capital. There is no minimum number of Debenture Units or minimum aggregate proceeds required to close the Offering and the Company may, at its discretion, elect to close the Offering in one or more tranches.","length":368,"tagName":"p"},{"type":"text","content":"In connection with the Offering, Company may pay a cash finder's fee of up to 8% of the gross proceeds of the Offering and may issue to certain eligible finders non-transferable broker...

More updates from Bionxt Solutions Inc